U.S. Revenue: $23.4 billion (up 6.8%)
Global Revenue: $48.1 billion (up 5%)
Top Brands: Prevnar ($5.7B), Lyrica ($5B), Ibrance ($2.1B), Lipitor ($1.8B), Viagra ($1.6B)
R&D Spend: $7.9B (up 2%), 16% of revenue
Planned Launches: Eucrisa (eczema)
Upcoming Patent Expirations: Viagra, Pristiq, Lyrica
Is Pfizer finally in a position to close the Lipitor chapter, the one titled “how to bounce back from monumental loss”? All signs indicate yes. A strong combo of M&A activity and a steady stream of new market arrivals seem to be the recipe for putting the pharma giant back on track. Multibillion-dollar prostate-cancer drug Xtandi was secured in a $14 billion acquisition of Medivation, while a $5.2 billion deal with Anacor Pharmaceuticals tapped into the atopic dermatitis market. Investors see the Medivation pickup as a slam dunk, but reservations remain about the potential of Anacor’s investigational product. Pfizer has a triple threat in oncology drug Ibrance, anticoagulant Eliquis (co-developed with Bristol-Myers Squibb), and RA drug Xeljanz, the firm’s fastest-growing drugs in 2016. Padded by global launches and a U.S. label expansion, Ibrance sales soared 190%, from $723 million in 2015 to $2.1 billion last year. Ibrance is expected to continue its domination of the CD4/6 class, although Novartis is releasing competitor Kisqali at an aggressive discount. Pfizer made its biosimilars debut with the 2016 launch of Inflectra. With eight biosimilars in mid to late development, the copycat of J&J’s Remicade is unlikely to be the last.
